Sabine Münkel

Title: Sabine Münkel: Innovator in Tumor Necrosis Factor Research

Introduction

Sabine Münkel is a prominent inventor based in Gärtringen, Germany. She has made significant contributions to the field of biomedical research, particularly in the development of selective antagonists for the human tumor necrosis factor type 1 receptor (huTNFR1). Her work aims to improve therapeutic options for various disorders related to huTNFR1.

Latest Patents

Münkel holds a patent for huTNFR1 selective antagonists. The present invention relates to a ligand that specifically binds to huTNFR1. This ligand includes one or more amino acid sequences of human origin that can reduce the immunogenic response in humans. Additionally, it contains sequences capable of selectively binding to huTNFR1. The invention also encompasses a nucleic acid sequence encoding the ligand and a pharmaceutical composition for treating disorders associated with huTNFR1. She has 1 patent to her name.

Career Highlights

Sabine Münkel is affiliated with the University of Stuttgart, where she conducts her research. Her work has garnered attention for its potential impact on therapeutic strategies in immunology and oncology.

Collaborations

Münkel collaborates with notable colleagues, including Peter Scheurich and Roland Kontermann. Their combined expertise enhances the research efforts in the field of tumor necrosis factor antagonism.

Conclusion

Sabine Münkel's innovative work in the development of huTNFR1 selective antagonists represents a significant advancement in biomedical research. Her contributions continue to pave the way for new therapeutic approaches in treating related disorders.